On December 22, 2025, the U.S. Food and Drug Administration (FDA) approved Wegovy (semaglutide) as a new dosage form. This significant regulatory action, designated as NDA 218316, was granted to sponsor NOVO, marking an important expansion for the therapeutic agent.
Background
Semaglutide, known by brand names including Wegovy, Ozempic, and Rybelsus, is a pharmaceutical agent with established uses. This approval for Wegovy (semaglutide) is categorized by the FDA as a Type 3 approval, specifically for a new dosage form. This classification applies to new formulations of drugs that have already received prior FDA approval.
What this means
The FDA's approval of a new dosage form for Wegovy (semaglutide) provides clinicians and patients with an expanded range of treatment options. New dosage forms can offer advantages such as improved convenience, alternative administration routes, or enhanced patient adherence, which are crucial factors in long-term therapy. This development could potentially broaden the accessibility or suitability of semaglutide for a wider patient population, depending on the specific characteristics of this newly approved formulation.
Source
The information regarding this FDA approval was sourced directly from the U.S. Food and Drug Administration (FDA) database. The approval for Wegovy (semaglutide), identified by NDA 218316, was officially recorded on December 22, 2025, and is accessible on the accessdata.fda.gov platform.